CAJ | 학술논문

目的：观察适丽顺(卵磷脂络合碘胶囊)治疗视网膜中央静脉阻塞有效性和安全性。方法回顾性分析84例84眼视网膜中央静脉阻塞患者的临床资料，应用适丽顺联合维脑路通口服作为治疗组，对照组仅给予维脑路通口服，并加强对高血压和糖尿病等原发病的治疗。其中43例缺血型视网膜中央静脉阻塞，在用药的过程中给予全视网膜规范光凝术治疗，其余41例为非缺血型视网膜中央静脉阻塞；3个月后观察两组不同类型的视网膜中央静脉阻塞眼底出血吸收情况，黄斑水肿恢复情况，视力提高情况，血常规和肝肾功情况。结果眼底出血吸收情况为研究组有效率为84.4%，对照组为62.5%，研究组的有效率高于对照组(P<0.01)；研究组视力提高率为78.1%，对照组为53.6%，研究组视力提高疗效优于对照组(P<0.01)。血常规及肝肾功未见异常。结论适丽顺治疗视网膜中央静脉阻塞可加快视网膜静脉阻塞患者的眼底出血吸收时间和提高患者视力，减少黄斑水肿的发生率，临床应用安全性好，值得临床广泛推广应用。
목적：관찰괄려순(란린지락합전효낭)치료시망막중앙정맥조새유효성화안전성。방법회고성분석84례84안시망막중앙정맥조새환자적림상자료，응용괄려순연합유뇌로통구복작위치료조，대조조부급여유뇌로통구복，병가강대고혈압화당뇨병등원발병적치료。기중43례결혈형시망막중앙정맥조새，재용약적과정중급여전시망막규범광응술치료，기여41례위비결혈형시망막중앙정맥조새；3개월후관찰량조불동류형적시망막중앙정맥조새안저출혈흡수정황，황반수종회복정황，시력제고정황，혈상규화간신공정황。결과안저출혈흡수정황위연구조유효솔위84.4%，대조조위62.5%，연구조적유효솔고우대조조(P<0.01)；연구조시력제고솔위78.1%，대조조위53.6%，연구조시력제고료효우우대조조(P<0.01)。혈상규급간신공미견이상。결론괄려순치료시망막중앙정맥조새가가쾌시망막정맥조새환자적안저출혈흡수시간화제고환자시력，감소황반수종적발생솔，림상응용안전성호，치득림상엄범추엄응용。
Objective To observe the Safety and ef ectiveness of using Shilishun (iodized lecithin capsules) for treatment of central retinal vein occlusion.Methods A retrospective analysis of the clinical data of 84 patients 84 eyes with central retinal vein occlusion,application of Shilishun Joint Venoruton oral as treatment group,the control group was given Venoruton oral,and strengthen the treatment for primary disease,such as hypertension and diabetes and so on.Among the 43 cases of ischemic central retinal vein occlusion, given photocoagulation for treatment of retinal specification in the medication process,the remaining 41 cases of non ischemic central retinal vein occlusion; 3 months after the observation of the two groups of dif erent types of central retinal vein occlusion fundus hemorrhage,macular edema recovery,visual acuity improvement,blood routine and liver and kidney function status.Results Retinal hemorrhage absorption:as the study group was 84.4%(54/43),the control group was 62.5%(35/11),the ef ective rate of study group was higher than that of the control group ( <0.01);the study group vision improvement rate was 78.1%(50/43),the control group was 53.6%(30/41),vision improvement of the research group was bet er than the control group ( <0.01).Blood routine and liver and kidney function was normal.Conclusion It can accelerate the absorption of retinal hemorrhage time and improve the visual acuity of using Shilishun to treat the central retinal vein occlusion,reduce the incidence of cystoid macular edema, and can reduce the non ischemic RVO into ischemic,clinical application security is good,worthy of clinical popularization and application.